Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM826JW)

• Drug Name: 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivative 6 Drug Info
• Synonyms: PMID27321640-Compound-45
• Cross-matching ID: TTD Drug ID: DM826JW

Molecule-Related Drug Atlas

Drug(s) Targeting Phosphodiesterase 2A (PDE2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[2]
CP-461	DMEYMTX	Inflammatory bowel disease	DD72	Phase 2	[3]
ND7001	DMUBTC6	Mood disorder	6A60-6E23	Phase 1	[4]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[1]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 2	DM4CSBD	N. A.	N. A.	Patented	[1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 2	DMS3ROL	N. A.	N. A.	Patented	[1]
Triazolo-pyridine derivative 5	DM1R205	N. A.	N. A.	Patented	[1]
PMID27321640-Compound-58	DM0NYK3	N. A.	N. A.	Patented	[1]
Triazolo-pyridine derivative 4	DM5ZQKS	N. A.	N. A.	Patented	[1]
Imidazo[5,1-c]pyrido[2,3-e][1,2,4]triazine derivative 3	DMZ61T8	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Phosphodiesterase 10A (PDE10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tofisopam	DMTGNWU	Hyperuricaemia	5C55.Y	Phase 2	[2]
TAK-063	DMP1873	Schizophrenia	6A20	Phase 2	[5]
PF-02545920	DMJPE61	Huntington disease	8A01.10	Phase 2	[6]
OMS824	DMA4OGL	Huntington disease	8A01.10	Phase 2	[7]
Lu AF11167	DMJOYNZ	Schizophrenia	6A20	Phase 2	[8]
FRM-6308	DMNCOE1	Schizophrenia	6A20	Phase 1b	[9]
PBF-999	DMBSQH9	Huntington disease	8A01.10	Phase 1	[10]
RG7203	DMYX4NP	Schizophrenia	6A20	Phase 1	[11]
AMG 579	DMRMC7U	Schizophrenia	6A20	Phase 1	[12]
Pyrido[3,2-e][1,2,4]triazolo[4,3-a]pyrazine derivative 1	DMC8935	N. A.	N. A.	Patented	[1]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Phosphodiesterase 10A (PDE10)	TTJW4LU	PDE10_HUMAN	Inhibitor	[1]
Phosphodiesterase 2A (PDE2A)	TTJGW1Z	PDE2A_HUMAN	Inhibitor	[1]

References

• [1] Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Expert Opin Ther Pat. 2016 Aug;26(8):933-46.
• [2] The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
• [3] Sulindac and its derivatives: a novel class of anticancer agents. Curr Opin Investig Drugs. 2001 May;2(5):677-83.
• [4] Phosphodiesterase 2 inhibitors promote axonal outgrowth in organotypic slice co-cultures. Neurosignals. 2013;21(3-4):197-212.
• [5] Characterization of Binding and Inhibitory Properties of TAK-063, a Novel Phosphodiesterase 10A Inhibitor. PLoS One. 2015; 10(3): e0122197.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] New Drugs/Drug News. P T. 2013 November; 38(11): 667-672.
• [8] PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178.
• [9] Massive schizophrenia genomics study offers new drug directions. Nat Rev Drug Discov. 2014 Sep;13(9):641-2.
• [10] Clinical pipeline report, company report or official report of Palobiofarma.
• [11] Synaptic synopsis. SciBX 6(41); doi:10.1038/scibx.2013.1153. Oct. 24, 2013
• [12] Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase10A (PDE10A). J Med Chem. 2014 Aug 14;57(15):6632-41.